1 COVID-19 Map. Johns Hopkins Coronavirus Resource Center. Accessed May 21, 2020.
https://coronavirus.jhu.edu/map.html.
2 Thompson C, Grayson N, Paton R, et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors – a pilot study of the value of serology to determine population exposure. medRxiv. Published online April 17, 2020.
doi:10.1101/2020.04.13.20060467.
3 Jerkovic I, Ljubic T, Basic Z, et al. SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia. medRxiv. Published online May 15, 2020.
doi:10.1101/2020.05.11.20095158.
4 Zou J, Bretin A, Gewirtz A. Antibodies to SARS/CoV-2 in arbitrarily-selected Atlanta residents. medRxiv. Published online May 6, 2020.
doi:10.1101/2020.05.01.20087478.
5 Doi A, Iwata K, Kuroda H, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study. medRxiv. Published online May 1, 2020.
doi:10.1101/2020.04.26.20079822.
6 Streeck H, Schulte B, Kuemmerer B, et al. Infection Fatality Rate of SARS-CoV-2 Infection in a German Community with a Super-Spreading Event. Infectious Diseases (except HIV/AIDS); 2020.
doi:10.1101/2020.05.04.20090076.
7 The New York Times. Cuomo Says 21% of Those Tested in N.Y.C. Had Virus Antibodies.
https://www.nytimes.com/2020/04/23/nyregion/coronavirus-new-york-update.html. Published April 23, 2020. Accessed May 21, 2020.
8 Saltzman J. Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus. The Boston Globe.
https://www.bostonglobe.com/2020/04/17/business/nearly-third-200-blood-samples-taken-chelsea-show-exposure-coronavirus/. Published April 17, 2020. Accessed May 21, 2020.
9 Governor Andrew M. Cuomo. Amid Ongoing COVID-19 Pandemic, Governor Cuomo Announces Results of State’s Antibody Testing Survey at Churches in Lower-Income NYC Communities of Color Show 27 Percent of Individuals Tested Positive for COVID-19 Antibodies. Published May 20, 2020. Accessed May 21, 2020.
https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-announces-results-states-antibody-testing-survey.
10 Stringhini S, Wisniak A, Piumatti G, et al. Repeated Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in a Population-Based Sample from Geneva, Switzerland. Infectious Diseases (except HIV/AIDS); 2020.
doi:10.1101/2020.05.02.20088898.
11 REPUBLIQUE ET CANTON DE GENEVE, Service du médecin cantonal. COVID-19 – Situation Épidémiologique, Canton de Genève Situation Au 21.05.2020 – 12h00, Selon Les Données Disponibles. Accessed May 21, 2020.
https://www.ge.ch/document/20094/telecharger.
12 Wang Y, Kang H, Liu X, Tong Z. Asymptomatic Cases with SARS-CoV-2 Infection. J Med Virol. n/a(n/a).
doi:10.1002/jmv.25990.
13 Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. Published online April 29, 2020:1-4.
doi:10.1038/s41591-020-0897-1.
14 Qu J, Wu C, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis Off Publ Infect Dis Soc Am. Published online April 27, 2020.
doi:10.1093/cid/ciaa489.
15 Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis Off Publ Infect Dis Soc Am. Published online March 28, 2020.
doi:10.1093/cid/ciaa344.
16 Tadini DE, Papamidimitriou-Olivgeris M, Opota O, et al. SARS-CoV-2, un point dans la tourmente. Rev Med Suisse. 2020 May 6;16(692):917–23.
17 Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: Challenges and pitfalls. Virus Res. 2014;194:175–83.
doi:10.1016/j.virusres.2014.03.018.
18 Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361–81.
19 Luo S, Cui W, Li C, et al. Seroprevalence of dengue IgG antibodies in symptomatic and asymptomatic individuals three years after an outbreak in Zhejiang Province, China. BMC Infect Dis. 2018;18(1):92.
doi:10.1186/s12879-018-3000-5.
20 Lienhard R. Pièges en sérologie infectieuse. Rev Med Suisse. 2011;7. Accessed May 23, 2020.
https://www.revmed.ch/RMS/2011/RMS-312/Pieges-en-serologie-infectieuse.
21 Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105(2):435–46.
22 Lin Q, Zhu L, Ni Z, Meng H, You L. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection. J Microbiol Immunol Infect. Published online March 25, 2020.
doi:10.1016/j.jmii.2020.03.015.23 Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737–41.
doi:10.1016/j.immuni.2020.04.012.24 Kwok KO, Lai F, Wei WI, Wong SYS, Tang JWT. Herd immunity – estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. 2020;80(6):e32-e33.
doi:10.1016/j.jinf.2020.03.027.
25 Lourenco J, Paton R, Ghafari M, et al. Fundamental Principles of Epidemic Spread Highlight the Immediate Need for Large-Scale Serological Surveys to Assess the Stage of the SARS-CoV-2 Epidemic. Epidemiology; 2020.
doi:10.1101/2020.03.24.20042291.
26 Glynn JR, Bower H, Johnson S, et al. Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus. Lancet Infect Dis. 2017;17(6):645–53.
doi:10.1016/S1473-3099(17)30111-1.
27 Dimech W, Mulders MN. A 16-year review of seroprevalence studies on measles and rubella. Vaccine. 2016;34(35):4110–8.
doi:10.1016/j.vaccine.2016.06.002
28 World Health Organization. Population-Based Age-Stratified Seroepidemiological Investigation Protocol for COVID-19 Virus Infection.; 2020.
https://www.who.int/publications-detail/population-based-age-stratified-seroepidemiological-investigation-protocol-for-covid-19-virus-infection.
29 Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860–8.
doi:10.1126/science.abb5793.
30 Goudsmit J. The paramount importance of serological surveys of SARS-CoV-2 infection and immunity. Eur J Epidemiol. Published online April 21, 2020:1–3.
doi:10.1007/s10654-020-00635-2.
31 Dimeglio C, Loubes J-M, Deporte B, et al. The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France. J Infect. Published online April 29, 2020.
doi:10.1016/j.jinf.2020.04.031.
32 Fontanet A, Tondeur L, Madec Y, et al. Cluster of COVID-19 in Northern France: A Retrospective Closed Cohort Study. Infectious Diseases (except HIV/AIDS); 2020.
doi:10.1101/2020.04.18.20071134.
33 Takita M, Matsumura T, Yamamoto K, et al. Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo. medRxiv. Published online May 5, 2020.
doi:10.1101/2020.04.29.20085449.
34 Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. medRxiv. Published online May 2, 2020.
doi:10.1101/2020.04.27.20082289.
35 Korth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020;128:104437.
doi:10.1016/j.jcv.2020.104437.
36 Devlin H. Coronavirus “game changer” testing kits could be unreliable, UK scientists say. The Guardian.
https://www.theguardian.com/world/2020/apr/05/coronavirus-testing-kits-could-be-unreliable-uk-scientists-say. Published April 5, 2020. Accessed May 23, 2020.
37 Okba NMA, Müller MA, Li W, et al. Early Release – Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients – Volume 26, Number 7–July 2020 – Emerging Infectious Diseases journal – CDC.
doi:10.3201/eid2607.200841.
39 SSPH+ Corona Immunitas. SSPH+. Accessed May 22, 2020.
https://www.corona-immunitas.ch.
40 Etude sur l’immunité collective auprès de la population | HUG – Hôpitaux Universitaires de Genève. Accessed May 22, 2020.
https://www.hug-ge.ch/coronavirus-maladie-covid-19/etude-sur-immunite-collective-aupres-population.
41 Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG Antibodies in Geneva, Switzerland (SEROCoV-POP): A Population-Based Study. Lancet. 2020 Jun 11;S0140-6736(20)31304-0.
doi: 10.1016/S0140-6736(20)31304-0. Online ahead of print.
42 COVID-19 - Situation épidémiologique, canton de Genève Situation au 21.05.2020 – 12h00, selon les données disponibles. Accessed May 22, 2020.
https://www.ge.ch/document/20094/telecharger.
43 Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The Role of Antibody Testing for SARS-CoV-2: Is There One? J Clin Microbiol. Published online April 29, 2020:JCM.00797-20, jcm;JCM.00797-20v1.
doi:10.1128/JCM.00797-20.
44 Bao L, Deng W, Gao H, et al. Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2. bioRxiv. Published online May 1, 2020:2020.03.13.990226.
doi:10.1101/2020.03.13.990226.
45 Phelan AL. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges. The Lancet. 2020;0(0).
doi:10.1016/S0140-6736(20)31034-5.
46 Perez-Saez J, Lauer SA, Kaiser L. Serology-informed estimates of SARS-COV-2 infection fatality risk in Geneva, Switzerland. MedRxiv (preprint). Published online June 12, 2020. doi:
https://doi.org/10.1101/2020.06.10.20127423.